Abstract 4616
Background
PD-L1 expression in malignancies contributes to an immunosuppressive microenvironment and disruption of anti-tumoral immune responses. Data are limited on the association between PD-L1 expression and survival in OSCC, overall and by HPV p16 status. We explored the prognostic effect of PD-L1 and p16 in localized or locally advanced OSCC treated with primary RT.
Methods
Patients (pts) diagnosed with OSCC from 2000-12 were identified from the Danish Head and Neck Cancer database (DAHANCA). PD-L1 expression was measured in tumor tissue using Agilent’s investigational PD-L1 imunohistochemistry (IHC) PharmDx Assay (clone 22C3). PDL1+ expression was defined as a score >1 using Tumor Proportion Score (TPS) as % of neoplastic cells expressing PDL1 at any intensity, Mononuclear Inflammatory Density Score (MIDS) as the estimate of PDL1 expressing mononuclear inflammatory cells associated with neoplastic cells, and Combined Positive Score (CPS) calculated using both TPS and MIDS. HPV oncogene expression was assessed using a > 70% cut-point for p16 IHC (clone E6H4). Data were analyzed using Cox proportional hazard model.
Results
303 OSCC pts with full clinical data, and PD-L1 and p16 staining were evaluated. Median follow up was 55 months (2-184). Median age (range) was 59 years (34-85), 72% were male, 91% had WHO 0-1 performance status, 55% were current smokers. All had primary RT, 66-68Gy, 2Gy/fx, 6 fx/wk, and 3% had concomitant cisplatin. 81% were UICC 7 stage 3-4 tumors. 55% were p16+. 76% were PD-L1+ by CPS, 35% by TPS, and 31% by MIDS. TPS was significantly associated with MIDS (Chi square p = 0.003). p16 was a strong prognostic factor for loco-regional control [crude hazard ratio (HR) of 0.31 (95% CI: 0.21-0.49)], disease-specific survival [0.39 (0.26-0.57)] and overall survival [0.34 (0.25-0.46)]. PD-L1 expressed as CPS, TPS or MIDS, was not prognostic of the clinical endpoints, overall or by p16 status. Adjustment for other covariates did not change the results.
Conclusions
PD-L1 expression is not prognostic in localized or locally advanced OSCC, including p16 positive disease. p16 is affirmed the strongest biological prognostic factor in OSCC.
Clinical trial identification
Legal entity responsible for the study
The Danish Head and Neck Cancer Group (DAHANCA).
Funding
Merck & Co, Inc.
Editorial Acknowledgement
Disclosure
T. Steiniche: Research funding: Merck & Co, Inc. P-T. Vo, D.R. Chirovsky: Employement, stock ownership, research funding, travel and accommodations expenses: Merck & Co, Inc. J. Cheng: Employment, stock ownership: Merck & Co. D. Aurora-Garg, R. Swaby: Employment Merck & Co. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract